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ReBACKGROUND The right ventricular outﬂow tract (RVOT) is acknowledged to be responsible for arrhythmogenesis in
Brugada syndrome (BrS), but the pathophysiology remains controversial.
OBJECTIVES This study assessed the substrate underlying BrS at post-mortem and in vivo, and the role for open
thoracotomy ablation.
METHODS Six whole hearts from male post-mortem cases of unexplained sudden death (mean age 23.2 years) with
negative specialist cardiac autopsy and familial BrS were used and matched to 6 homograft control hearts by sex and
age (within 3 years) by random risk set sampling. Cardiac autopsy sections from cases and control hearts were stained
with picrosirius red for collagen. The RVOT was evaluated in detail, including immunoﬂuorescent stain for connexin-43
(Cx43). Collagen and Cx43 were quantiﬁed digitally and compared. An in vivo study was undertaken on 6 consecutive
BrS patients (mean age 39.8 years, all men) during epicardial RVOT ablation for arrhythmia via thoracotomy. Abnormal
late and fractionated potentials indicative of slowed conduction were identiﬁed, and biopsies were taken before
ablation.
RESULTS Collagen was increased in BrS autopsy cases compared with control hearts (odds ratio [OR]: 1.42; p ¼ 0.026).
Fibrosis was greatest in the RVOT (OR: 1.98; p ¼ 0.003) and the epicardium (OR: 2.00; p ¼ 0.001). The Cx43 signal was
reduced in BrS RVOT (OR: 0.59; p ¼ 0.001). Autopsy and in vivo RVOT samples identiﬁed epicardial and interstitial
ﬁbrosis. This was collocated with abnormal potentials in vivo that, when ablated, abolished the type 1 Brugada elec-
trocardiogram without ventricular arrhythmia over 24.6  9.7 months.
CONCLUSIONS BrS is associatedwith epicardial surface and interstitial ﬁbrosis and reduced gap junction expression in the
RVOT. This collocates to abnormal potentials, and their ablation abolishes the BrS phenotype and life-threatening arrhyth-
mias. BrS is also associatedwith increased collagen throughout the heart. Abnormalmyocardial structure and conduction are
therefore responsible for BrS. (J Am Coll Cardiol 2015;66:1976–86) © 2015 by the American College of Cardiology
Foundation. Published byElsevier Inc. This is an open access article under the CCBY license (http://creativecommons.org/
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LV = left ventricle/ventricular
OR = odds ratio
PSR = picrosirius red stain
RV = right ventricular
RVOT = right ventricular
outﬂow tract
SADS = sudden arrhythmic
death syndrome
SCD = sudden cardiac death
SCN5A = sodium channel,
voltage gated, type V alpha
subunit
VT = ventricular tachycardia
VF = ventricular ﬁbrillation
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1977B rugada syndrome (BrS) is an inheritedarrhythmia syndrome diagnosed by the pres-ence of the type 1 Brugada electrocardiogram
(ECG) (1). It was initially described in survivors of car-
diac arrest without structural disease (2), and it is
partly responsible for sudden arrhythmic death syn-
drome (SADS) (1,3,4). Potential causal variants in the
cardiac sodium channel gene SCN5A are identiﬁed
in 20% of cases (5). It was initially proposed that the
basis for BrS was an abnormal transmural repolariza-
tion in the right ventricular outﬂow tract (RVOT) due
to heterogeneous loss of the cardiomyocyte action
potential dome in the epicardium (6). However,
electrophysiological, imaging, and histopathological
studies have identiﬁed subtle structural abnormal-
ities in patients with BrS (7–9). Myocardial ﬁbrosis
has been suggested by abnormal, low-voltage, frac-
tionated electrograms localized to the RVOT at the
epicardium (9,10). Ablation at these sites has elimi-
nated the type 1 Brugada ECG pattern and success-
fully reduced arrhythmic events (10), as was seen in
a previous experimental model (11).SEE PAGE 1987A study of sudden cardiac death (SCD) cases asso-
ciated the type 1 ECG with arrhythmogenic right
ventricular cardiomyopathy (8). Furthermore, SCD
cases with a familial diagnosis of BrS showed struc-
tural abnormalities that were insufﬁcient to fulﬁll the
diagnostic criteria for cardiomyopathy or myocarditis
(12). Other myocardial anomalies have been reported
in selected cases (13,14). Therefore, there is sig-
niﬁcant debate about the underlying substrate in
BrS (15).
To resolve this controversy, we tested the hy-
pothesis that BrS is associated with ﬁbrosis in the
RVOT and altered expression of the gap junction
protein connexin-43 (Cx43), which may be critical for
correct cellular migration and maintenance of RVOT
zonation (16,17). We expected this to manifest as
abnormal late and fractionated potentials at the RVOT
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STUDY SETTING AND COHORTS. Post-mortem
BrS cohort . From 2005 to 2010, 1,304 unex-
pected SCD cases were referred for specialist
cardiac autopsy. We studied 6 male cases
(B1 to B6; mean age 23.2 years) (Table 1),
which fulﬁlled the following criteria for SADS
(1): 1) age 1 to 64 years; 2) unexpected sudden
death; 3) whole heart available; 4) heart
morphologically normal at coronial/medical
examiner and specialist cardiac autopsies;
5) no antemortem cardiac conditions; and
6) negative toxicological analysis. In addition,
1 or more ﬁrst-degree blood relatives had
to be diagnosed with BrS (Online Methods)
following familial evaluation (1,18,19).
All 6 cases were asymptomatic before
death, according to primary care records and
family interview, with no family history of
premature death. Five died at rest (4 during
sleep) and 1 during exertion. None had un-
dergone previous cardiac investigation.
Post-mortem contro l cohort . Six control cases (C1
to C6) (Table 1) of premature noncardiac death were
identiﬁed from 407 consecutive homograft valve do-
nors from Hareﬁeld Hospital, London (2010 to 2012).
These were matched to the post-mortem BrS cases by
random risk set sampling selection for age (within
3 years) and sex in a 1:1 ratio. Inclusion criteria for
control cases were: 1) age 1 to 64 years; 2) absence of
antemortem cardiac symptoms (syncope or seizures);
3) normal specialist cardiac autopsy; and 4) intact
RVOT.
In v ivo BrS ablat ion cohort . Six symptomatic male
BrS patients (mean age 39.8 years) (Table 1) under-
going mapping and RVOT ablation during open
thoracotomy were studied at Bhumibol Adulyadej
Air Force Hospital (cases V1 to V5, Bangkok) and
Yokohama Rosai Hospital (case V6, Japan). All
had an implantable cardioverter deﬁbrillator (ICD)
before recruitment, with a clinical diagnosis (Online
Methods) of BrS (1,19), and normal echocardiography,t White Memorial Medical Center, and the Vejdusit
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TABLE 1 Demographic Data, Familial Evaluation Results, and Index Presentation for the Included Post-Mortem BrS,
Post-Mortem Control, and In Vivo BrS Cases








B1 M 15 SCD in sleep Diagnosis in relative Normal 2 2
B2 M 18 SCD in sleep Diagnosis in relative Normal 4 1
B3 M 19 SCD in sleep Diagnosis in relative Normal 5 1
B4 M 23 SCD with exercise Diagnosis in relative Tunneled RCA 3 2
B5 M 24 SCD in sleep Diagnosis in relative Atrial septal defect 3 1
B6 M 40 SCD with minimal activity Diagnosis in relative Normal 5 3
Post-mortem control cohort
C1 M 17 RTA None Normal — —
C2 M 18 RTA None Normal — —
C3 M 22 Suicide None Normal — —
C4 M 22 RTA None Normal — —
C5 M 22 RTA None Normal — —
C6 M 37 Homicide None Normal — —
In vivo BrS cohort
V1 M 48 Multiple syncope Spontaneous type 1 ECG Normal — —
V2 M 28 Multiple syncope Ajmaline-provoked type 1 ECG Normal — —
V3 M 59 VF arrest Spontaneous type 1 ECG Normal — —
V4 M 29 VF arrest with fever Spontaneous type 1 ECG Normal — —
V5 M 47 Syncope Spontaneous Type 1 ECG Normal — —
V6 M 27 Multiple syncope Spontaneous type 1 ECG Normal — —
BrS ¼ Brugada syndrome; ECG ¼ electrocardiogram; M ¼ male; RCA ¼ right coronary artery; RTA ¼ road trafﬁc accident; SCD ¼ sudden cardiac death; VF ¼ ventricular
ﬁbrillation.
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1978computed tomography/magnetic resonance imaging,
and coronary angiography. Thoracotomy was indi-
cated for ICD lead extraction (V1, V2, V5, and V6) or to
permit epicardial access for ablation after a failed
percutaneous attempt (V3 and V4).
MUTATION ANALYSIS. In vivo BrS subjects and
clinically affected blood relatives of post-mortem
cases were counseled and offered SCN5A mutation
analysis. Mutation analysis was not undertaken in the
autopsy cases due to lack of suitable unﬁxed material.
SPECIALIST CARDIAC POST-MORTEM EXAMINATION. A
systematic specialist post-mortem of the whole heart
was undertaken, with macroscopic and microscopic
evaluation in all referred SCD cases and control
hearts, blinded to the results of familial evaluation
(20). At least 20 tissue sections were sampled from
each case, including the following: coronary arteries;
ascending aorta; 4 sequential sections from the
atrioventricular node to the branches of the His-
Purkinje system; 4 sinoatrial node sections; and 2
RVOT sections. Sectioning of the anterior, lateral, and
posterior left ventricle (LV), anterior and posterior
interventricular septum, and right ventricle (RV) was
performed at the midventricular level. Histological
examination (Online Methods) was performed with
hematoxylin and eosin and elastic Van Gieson stains.DETAILED POST-MORTEM RVOT EXAMINATION. Up
to 14 parallel longitudinal sections of 3-mm thickness
were taken from the RVOT in each post-mortem
subject to ensure complete examination of this region.
Morphometric analysis for post-mortem myocardial
collagen/ﬁbrosis. All post-mortemRVOT sectionswere
stained with the picrosirius red (PSR) technique, with
RV free wall and LV tissue for comparison. These sec-
tions (n ¼ 267, total area quantiﬁed 6,505 mm2) were
digitized (Scanscope CS, Aperio, California) at 20
magniﬁcation in 24-bit color. Computational semi-
automated morphometric analysis was performed on
5magniﬁcation images of transmural tissue sections
on the basis of green color depth thresholds (ImageJ,
National Institutes of Health, Bethesda, Maryland),
with blinding to the diagnosis and cardiac wall.
Epicardial, mid-myocardial, and endocardial zones
and fat cells were deﬁned by consensus (Figure 1A).
Regions of collagen and fat were deﬁned by color
threshold, with proportions calculated by cardiac wall
and tissue zone relative to tissue area.
Confoca l mic roscopy ana lys i s of post -mortem
Cx43 dist r ibut ion . An RVOT section from each
post-mortem case underwent Cx43 immunoﬂuores-
cent staining (Online Methods) to evaluate gap junc-
tion remodeling. Three transmural tissue strips of
450 mm width with intact myocardium per case
FIGURE 1 Morphometric Analysis of Histological Stained Sections
(A) Morphometric analysis of a single tissue section. (A1) Visually deﬁned tissue zones
(yellow polygons) deﬁning the epicardium, mid-myocardium, and endocardium. (A2)
Collagen (black). (A3) Fat cells (black). (B) Representative serial myocardial strips from
the post-mortem control group for collagen correction for Cx43 morphometric analysis.
(B1) Myocardial strip of Cx43 expression. (B2) Serial section aligned to B1, stained with
PSR. (B3) A threshold drawing generated from the PSR-stained myocardium image
(as created by ImageJ). Scale bar ¼ 200 mm; Cx43 ¼ connexin-43; PSR ¼ picrosirius red.
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1979were identiﬁed using 40,6-diamidino-2-phenylindole
immunoﬂuorescence, blinded to the Cx43 signal. A
Zeiss LSM-780 (Carl Zeiss Ltd., Cambridge, United
Kingdom) inverted confocal microscope (20, 0.8 nu-
merical aperture objective lens) with sequential
channel scanning (Alexa Fluor 488, 40,6-diamidino-2-
phenylindole, and cyanine Cy3 ﬂuorescence) in a
single optical plane was used. Cx43 was deﬁned by
color threshold (ImageJ). Perinuclear lipofuscin was
excluded.
Morphometric analysis of Cx43 was performed as
for collagen. Serial sections immediately adjacent to
the Cx43-stained strip were imaged with PSR to
permit correction for collagen content (Figure 1B) by
dividing by the proportion representing the non-
collagenous component. Adjusted and unadjusted
Cx43 proportions were aggregated per subject.
IN VIVO OPEN THORACOTOMY MAPPING AND
ABLATION OF RVOT. Cases V1 to V4 underwent mini-
lateral thoracotomy to expose the anterior RVOT,
whereas cases V5 and V6 had a midline thoracotomy.
For cases V1 to V5, epicardial mapping was performed
with a 3.5-mm-tip ThermoCool catheter (Biosense
Webster, Diamond Bar, California) limited to the
anterior RVOT (Figure 2). Radiofrequency ablations
with 20- to 45-W energy were performed off pump at
substrate sites identiﬁed by abnormal late and frac-
tionated electrograms. For case V6, electroanatomical
mapping was performed with the CARTO 3 System
(Biosense Webster) intraoperatively, with manual
conﬁrmation of abnormal electrogram amplitudes.
Cryoablation was then performed at sites of abnormal
late potentials following total cardiopulmonary bypass
with aorta-bicaval cannulation. The ablation endpoint
for all cases was elimination of abnormal late and
fractionated electrograms in the RVOT epicardium.
BIOPSY OF IN VIVO SUBSTRATE SITES IN THE RVOT.
All sites identiﬁed with abnormal electrograms were
biopsied under direct vision: off-pump sampling
(cases V1 to V5) was limited to small samples of
epicardial surface and myocardial tissue to minimize
complications; transmural biopsies were taken during
heart–lung bypass in case V6. Biopsy tissue was
stained with PSR.
CLINICAL ENDPOINTS. In vivo BrS subjects were
reviewed 1 month post-ablation and every 3 months
thereafter with ICD interrogation and ECG. Ajmaline
provocation was performed at 6 months for patients
recruited from Bangkok.
RESEARCH GOVERNANCE. The following institu-
tional review boards approved the study: London
Stanmore Research Ethics Committee; Bhumibol
Adulyadej Air Force Hospital; and Yokohama RosaiHospital. Informed consent was obtained from sub-
jects and/or next of kin.
STATISTICAL ANALYSIS. Analysis was undertaken
using Stata v12.1 (StataCorp LP, College Station,
Texas). Natural log transformation corrected skew
in measured tissue proportions of ﬁbrosis and fat
before analysis by simple and multiple regression
(using independent factors for disease status,
myocardial wall, and myocardial region) with robust
variances; analyses are reported as odds ratios (OR).
A p value #0.05 was considered signiﬁcant.
RESULTS
POST-MORTEM DIAGNOSIS OF BRUGADA SYNDROME
ON FAMILIAL CARDIAC EVALUATION. A mean of 3.7
ﬁrst-degree blood relatives per post-mortem BrS case
underwent familial evaluation, with 1.7 diagnosed
with BrS on average. One relative of B4 was diag-
nosed with BrS on the basis of a spontaneous type 1
FIGURE 2 Computed Tomography Scan, Epicardial Electrograms, and Histology of RVOT of In Vivo BrS Patient
Computed tomography scan of the heart (center) of in vivo BrS patient V2 showing an anatomical grid over the anterior RVOT. ECG lead II and a
distal bipolar (0.4 mV/cm voltage scale at 30- to 300-Hz ﬁlter settings) and unipolar (5 mV/cm voltage scale at 0.05- to 300-Hz ﬁlter settings)
electrogram at labeled sites are given in surrounding panels, with pacing stimuli indicated by red arrowheads. Abnormal fractionated elec-
trograms are on the (A to C) left and normal electrograms on the (D to E) right. (F) Epicardial biopsy and histology (PSR) at the site of the
abnormal electrogram shows epicardial ﬁbrosis with focal ﬁnger-like projections of collagen into myocardium. ABL d ¼ distal bipolar ablation
catheter electrogram; ABL uni ¼ unipolar ablation catheter electrogram; BrS ¼ Brugada syndrome; RVOT ¼ right ventricular outﬂow tract;
other abbreviations as in Figure 1.
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1980Brugada ECG pattern, with other relatives identiﬁed
following ajmaline provocation (Figure 3). No rela-
tives had evidence of structural or functional
myocardial disease on cardiac imaging.
GENETIC MUTATION ANALYSIS. Five of the 6
families of post-mortem BrS cases consented to
genetic analysis; 2 affected relatives of B4 were
found to carry the p.Leu1462Gln mutation in
SCN5A. Poor quality of extracted DNA prevented
conﬁrmation in B4. All in vivo cases underwentgenetic testing and 2 SCN5A mutation carriers
were identiﬁed (case V4 p.Ser528Cys and case V6
p.Leu846Arg).
COLLAGEN STAINING AND MYOCARDIAL ARCHITECTURE
OF THE RVOT. Myocardial collagen in the control
group was seen in the epicardial surface and around
blood vessels. Linear collagen was distributed parallel
to myocytes, but did not surround the individual
myocytes (Figure 4A2 and 4A3). This collagen distri-
bution pattern is normal in the RV.
FIGURE 3 Right Precordial ECG Traces From Blood Relatives of Post-Mortem BrS Cases During Ajmaline Provocation
ECG traces acquired following cranial displacement of electrode positions V1 and V2 into 2ics. 2ics ¼ second intercostal space; other
abbreviations as in Figures 1 and 2.
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1981In the post-mortem BrS group, there was an
appearance of increased epicardial surface collagen
that was thicker than that in control hearts, indicating
epicardial ﬁbrosis (Figure 4B1). There was inﬁltration
of the epicardial surface ﬁbrosis into the underlying
epicardial myocardium, with individual myocytes
surrounded by collagen, which was considered
interstitial myocardial ﬁbrosis (Figure 4B2). There was
also evidence of replacement of myocytes by
collagen, focal replacement ﬁbrosis, admixed with fat
in the epicardial myocardium (Figure 4B3). The
in vivo tissue samples taken in the regions of late
potentials showed similar epicardial and myocardial
ﬁbrosis patterns (Figure 4C1 to 4C3). The epicardial
ﬁbrosis appeared to be separated from the underlying
myocardium by fat in some sections, whereas in
others, it inﬁltrated directly into the underlying
myocardium.
MORPHOMETRIC ANALYSIS OF POST-MORTEM
COLLAGEN BY PSR. The BrS cohort had greater
collagen content than control hearts, with maximal
differences seen in the RVOT epicardium (13.9% vs.10.5%; p ¼ 0.024) (Figure 5A). Multivariable analysis
(Table 2) identiﬁed that the diagnosis of BrS was
associated with an OR of 1.42 (p ¼ 0.026) for collagen
proportion, regardless of the cardiac chamber.
Control hearts and cases also showed similar pat-
terns of collagen distribution, but this was greater in
cases. The RVOT (OR: 1.98; p ¼ 0.003) and RV (OR:
1.66; p ¼ 0.020) walls had higher collagen content in
comparison with the LV, irrespective of diagnosis.
Similarly, a gradient of decreasing collagen content
was seen from the epicardial to endocardial zones
(OR: 2.00; p ¼ 0.001) in all chambers.
MORPHOMETRIC ANALYSIS OF POST-MORTEM FAT
CELLS. Regression analysis for the proportion of fat
content in the myocardium showed no signiﬁcant
difference between BrS and control hearts (p ¼ 0.133).
POST-MORTEM Cx43 SIGNAL DISTRIBUTION AND
QUANTIFICATION. In control myocardial tissue, Cx43
localized to the intercalated disc (Figure 4A4 and 4A5).
BrS cases showed a reduced Cx43 signal and a
decreased punctate pattern in the intercalated disc
(Figure 4B4 and 4B5).
FIGURE 4 RVOT Histological Sections Stained for Collagen and Immunoconfocal Images of Cx43 Expression
RVOT histological sections stained for collagen (purple-red) with PSR and immunoconfocal images of gap junction protein Cx43 expression
(green ﬂuorescence). Sections from (A) post-mortem control, (B) post-mortem BrS cases, and (C) in vivo BrS patients. (A) Post-mortem
control. PSR: (A1) normal epicardial collagen thickness, with (A2) linear collagen between myocytes and (A3) around blood vessels, but no
evidence of complete circumscription of myocytes by collagen. Cx43: (A4) normal appearance of gap junction signal concentrated to form
transverse stripes, with an organized parallel orientation. (A5) Clusters of gap junctions in a typical ring-like formation at the intercalated disc,
with large gap junctions circumscribing the periphery of the disc and smaller junctions in the inner region. (B) Post-mortem BrS. PSR: (B1)
thickened epicardial collagen layer, with (B2) evidence of interstitial ﬁbrosis, identiﬁed by collagen circumscribing myocytes, and (B3)
replacement ﬁbrosis, identiﬁed by replacement of myocytes by collagen in a region of inﬁltration by fat. Cx43: (B4) notable dispersion of the
signal along the axis of the cell and (B5) sparse junctional plaque with an ill-deﬁned border. (C) In vivo BrS. PSR: (C1) thickened epicardial
collagen layer with (C2) evidence of interstitial ﬁbrosis, identiﬁed by collagen circumscribing myocytes, and (C3) replacement ﬁbrosis, identiﬁed
by replacement of myocytes by collagen. Abbreviations as in Figures 1 and 2.
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1982BrS cases had reduced Cx43 signal in the RVOT
compared with control hearts (OR: 0.59; p ¼ 0.001)
(Figure 5B, Table 3), even following correction for
collagen content (OR: 0.58; p ¼ 0.036). No signiﬁcant
difference was observed between myocardial zones of
the RVOT (p ¼ 0.476).
CLINICAL OUTCOMES. The mean radiofrequency
ablation time was 14  6 min per in vivo BrS case; no
surgical complications occurred. In the 5 patients
who underwent radiofrequency ablation, frac-
tionated electrograms disappeared immediately, with
a drastic reduction of ventricular electrograms after
radiofrequency was turned off. The ECG pattern
normalized (i.e., reversion from type 1 Brugada ECG
pattern) within a week in all cases, and a negative
ajmaline test was seen in those who underwent sub-
sequent provocation 3 months later (n ¼ 5 of 6). No
further ventricular tachycardia (VT) or ventricular
ﬁbrillation (VF) episodes were seen during the follow-up period (mean 24.6  9.7 months, median 25 months),
and quinidine therapy was not required.
DISCUSSION
This study systematically describes increased
collagen content in the RVOT that shows epicardial
surface and intramyocardial ﬁbrosis, as well as
diminished gap junction protein expression. In vivo
human evidence of conduction delay in the RVOT was
associated with similar patterns of ﬁbrosis, corrobo-
rating the post-mortem ﬁndings (Central Illustration).
Ablation at these sites eliminated the type 1 ECG
pattern with successful suppression of VT/VF recur-
rence, giving support to the hypothesis that con-
duction delay is responsible for the BrS phenotype.
MYOCARDIAL FIBROSIS. Despite the a priori
exclusion at expert autopsy of overt structural abnor-
malities in SADS cases, the diagnosis of BrS was
associated with increased collagen content in all
FIGURE 5 Scatterplot of Collagen and Cx43Quantiﬁcation in the Epicardial Myocardium


































(A) PSR quantiﬁcation of collagen content and (B) immunoﬂuorescence quantiﬁcation of
Cx43. Orange data points represent distribution means. Blue data points represent indi-
vidual cases and controls. Abbreviations as in Figures 2 and 3.
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1983ventricular walls. This was over and above the normal
collagen seen in age- and sex-matched control hearts.
In addition, the in vivo cases all had normal cardiac
imaging, including computed tomography/magnetic
resonance imaging, as well as macroscopically normal
hearts on direct visualization during thoracotomy.
These cases, therefore, represent minimally structur-
ally perturbed candidates for the diagnosis of BrS, yet
they showed distinctive patterns of ﬁbrosis. This re-
veals the limitations of current imaging technology for
detecting subtle changes in the myocardium that can
still give rise to physiologically detectable changes.
We have identiﬁed previously that one-third of
unexplained SCDs with idiopathic ﬁbrosis and/or
hypertrophy had familial diagnoses of BrS (12). LV
and RV free-wall, age-related ﬁbrosis has also been
seen in mouse models of BrS (21,22). In addition, we
identiﬁed epicardial and intramyocardial ﬁbrosis at
the site of epicardial late potentials in the RVOT of
BrS patients. A detailed study of a single patient with
BrS who underwent transplantation has previously
colocalized interstitial ﬁbrosis with conduction delay
(14). Moreover, murine models of BrS, including
epicardial electrophysiological study of Langendorff
perfused hearts, have shown RVOT pathology:
increased collagen; delayed conduction; and a pro-
pensity for ventricular arrhythmia with programmed
stimulation in the RVOT (23). It is therefore plausible
that BrS may reﬂect a generalized disease of myo-
cardial architecture, with baseline properties of the
RVOT predisposing it to ﬁbrosis, which is likely to
underlie the condition and arrhythmic risk (24).
Interestingly, although ﬁbrosis and conduction delay
have been identiﬁed in carriers of SCN5A mutations
(25), all cases demonstrated some evidence of
ﬁbrosis, whether they harbored an SCN5Amutation or
not. The reported increase in proﬁbrotic markersTABLE 2 Univariable and Multivariate Regression Analysis of
Proportional Collagen Content, as Evaluated by Morphometric
Analysis of PSR Staining in BrS Cases Versus Control Hearts
Variable
BrS vs. Control Hearts
Univariable Analysis Multivariate Analysis
OR (95% CI) p Value OR (95% CI) p Value
Disease 1.42 (1.06–1.90) 0.024 1.42 (1.05–191) 0.026
LV 1.00 N/A 1.00 N/A
RV 1.66 (1.11–2.50) 0.019 1.66 (1.10–2.51) 0.020
RVOT 1.98 (1.34–2.91) 0.003 1.98 (1.33–2.93) 0.003
Endo 1.00 N/A 1.00 N/A
Mid 1.27 (1.02–1.58) 0.033 1.27 (1.02–1.58) 0.035
Epi 2.00 (1.46–2.73) <0.001 2.00 (1.45–2.74) 0.001
BrS ¼ Brugada syndrome; CI ¼ conﬁdence interval; Endo ¼ endocardium; Epi ¼
epicardium; LV ¼ left ventricle; Mid ¼ mid-myocardium; OR ¼ odds ratio; PSR ¼
picrosirius red; RV ¼ right ventricle; RVOT ¼ right ventricular outﬂow tract.secondary to sodium channel inactivation, indepen-
dent of messenger ribonucleic acid expression, sug-
gests that ﬁbrosis may be a feature irrespective of
mutation status (26).
FAT INFILTRATION OF MYOCARDIUM. No signiﬁcant
difference in fat content was observed between
BrS cases and control hearts. In contrast, transmural
fat inﬁltration in the absence of ﬁbrosis predomi-
nated in Italian post-mortem cases with the Brugada
ECG pattern (8). This difference may reﬂect the in-
clusion of patients with overt antemortem and post-
mortem features of arrhythmogenic right ventricular
cardiomyopathy in the Italian study without suitable
age- and sex-matched controls.
SIGNIFICANCE OF Cx43. The Cx43 signal was dimin-
ished in BrS compared with the control myocardium.TABLE 3 Multivariable Regression Analysis of Proportional
Connexin43 Content in BrS Post-Mortem Cases Versus
Control Hearts
Variable
BrS vs. Control Hearts
OR (95% CI) p Value
Disease 0.59 (0.44–0.79) 0.001
Endocardium 1.00 N/A
Mid-myocardium 0.97 (0.64–1.49) 0.897
Epicardium 1.16 (0.76–1.78) 0.476
Disease (corrected for collagen) 0.58 (0.36–0.96) 0.036
Expressionaccording to zoneandafter correction for collagencontent is also shown.
Abbreviations as in Table 2.
CENTRAL ILLUSTRATION Pathophysiology of Brugada Syndrome: Conduction Delay Due to Fibrosis and
Connexin-43 Abnormalities
Nademanee, K. et al. J Am Coll Cardiol. 2015; 66(18):1976–86. 
Conduction delay in the right ventricular outﬂow tract (RVOT) is caused by myocyte electrical uncoupling due to a reduction in connexin-43 at endplates
and subtle interstitial and replacement ﬁbrosis. As a result, epicardial electrograms are abnormal, slowed, and fragmented. This provides the substrate for
the Brugada type 1 electrocardiographic (ECG) pattern, re-entry, and the generation of polymorphic ventricular tachycardia (VT) and ventricular ﬁbrillation.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Two main the-
ories have been proposed to explain the pathophysiology of BrS: 1)
that it is due to either dispersed repolarization; or 2) to abnormal
depolarization due to conduction delay. Tissue from cases of SCD
due to BrS without evident structural disease exhibits increased
collagen throughout the heart and ﬁbrosis, as well as reduced gap
junction signaling protein Cx43 in the RVOTs of those with BrS
compared with tissue from victims of noncardiac death. Myocar-
dial biopsies before epicardial ablation also display ﬁbrosis at sites
of delayed activation in patients with BrS. These data support the
depolarization hypothesis.
TRANSLATIONAL OUTLOOK: Future studies should address
the roles of quantiﬁcation of ﬁbrosis and gap junction proteins in
the diagnosis of and risk stratiﬁcation for SCD among patients
with known or suspected BrS and identify the predictors and
determinants of these structural abnormalities.
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1985This raises the possibility that changes at the interca-
lated disc that affect Cx43 expression may cause car-
diomyocyte electrical uncoupling, and therefore, may
be important in the pathogenesis of BrS. Royer et al.
(21) describe diminished Cx43 expression in the scn5a-
knockoutmousemodel’s myocardium, which is a clear
correlation with the human phenotype.
OPEN THORACOTOMY CATHETER ABLATION. As previ-
ously reported (10), abolition of the type 1 ECG and
suppression of VT/VF episodes in a high-risk BrS pa-
tient cohort were seen following epicardial ablation at
sites of late potentials in the RVOT. To our knowl-
edge, this study reports, for the ﬁrst time, a surgical
approach with either midline or mini-lateral thora-
cotomy to access the epicardial surface of the RVOT
for ablation.
DEPOLARIZATION VERSUS REPOLARIZATION. Our
ﬁndings reinforce other human studies that have
identiﬁed conduction delay in the RVOT in BrS in vivo
(10,27–30). Two of these studies used noncontact
intracardiac mapping or noninvasive ECG imaging
and proposed additional repolarization abnormalities
(27,30). We have correlated directly acquired delayed,
prolonged, and fragmented epicardial electrograms
and histopathological evidence for ﬁbrosis that sup-
port depolarization delay as the primary substrate.
STUDY LIMITATIONS. Subject recruitment was limited
by the rarity of thoracotomy in BrS patients and the
availability of whole hearts post-mortem in which
families were diagnosed with BrS. Thus, our cohorts
represent a unique collection. Both control and case
hearts went through similar processing after death,
with an approximate 24- to 48-h delay before ﬁxation
and an intervening period of refrigeration. We were
unable to establish more accurate timing.
The etiology of death in the 6 BrS post-mortem
cases was established by identifying BrS in blood
relatives in the absence of alternative explanations.
This methodology forms the basis of internationally
accepted guidelines for the diagnosis of genetic dis-
orders in unexplained SCD and BrS (1,3). However, we
recognize that without previous ECG evidence, we
cannot be absolutely certain of the diagnosis. None-
theless, it is a reasonable assumption, as the deceased
young person does, at a minimum, have a 50% chance
of having the same diagnosis. The chance of any other
diagnosis is much smaller. In addition, the ﬁnding of 1
SCN5A mutation in the 5 families tested is consistent
with the established prevalence of 20% in BrS (5).
Retrospective investigation by molecular autopsy was
not possible in our cases, although the absence of a
mutation would not exclude BrS due to the low mo-
lecular genetic yield (5).Our study only included symptomatic BrS cases.
Thus, our observations may reﬂect a biased popu-
lation of high-risk subjects. However, myocardial
ﬁbrosis has also been identiﬁed in low-risk living
patients on magnetic resonance imaging (31,32) and
histopathology (33).
CONCLUSIONS
BrS, in the absence of overt structural or functional
abnormalities, is unequivocally associated with
increased collagen, ﬁbrosis, and reduced gap junction
expression in the RVOT. Myocardial late potentials
indicative of the arrhythmic substrate anatomically
collocate with ﬁbrosis in the RVOT of BrS subjects.
Therefore, it is plausible that BrS represents a disease
of myocardial architecture and cardiomyocyte elec-
trical coupling in the RVOT. The reduction in
arrhythmic burden and reversal of electrocardio-
graphic signature of BrS following ablation at these
sites supports our hypothesis that these myocardial
changes result in discontinuity of cardiac conduction
responsible for arrhythmogenesis. These data are the
strongest yet to support the depolarization theory of
the pathogenesis of BrS (29,34).
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